Picture of DRI Healthcare Trust logo

DHT.UN DRI Healthcare Trust Share Price

0.000.00%
ca flag iconLast trade - 00:00
HealthcareBalancedMid CapNeutral

Momentum

Relative Strength (%)
1m+11.46%
3m+3.32%
6m+0.81%
1yr+8.31%
Volume Change (%)
10d/3m+146.93%
Price vs... (%)
52w High-3.78%
50d MA+9.96%
200d MA+14.79%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)5.4
PEG Ratio (f)0.09
EPS Growth (f)146.92%
Dividend Yield (f)3.11%
Valuation (ttm)IndustryMarket
Price to Book Value1.67
Price to Tang. Bookn/a
Price to Free Cashflow6.75
Price to Sales3.69
EV to EBITDA13.33

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-2.13%
Return on Equity-10.42%
Operating Margin-9.04%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202631st Dec 2027
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2026 / 2027

Blurred out image of DRI Healthcare Trust EPS forecast chart

Profile Summary

DRI Healthcare Trust is a global pharmaceutical royalty monetization company. The Company's portfolio consists of 29 royalty streams on 23 products that treat conditions in a number of therapeutic areas, including oncology, neurology, ophthalmology, endocrinology, hematology, dermatology, as well as lysosomal storage disorders (LSD) and immunology. Its Royalty Assets include Ekterly, Eylea I, Eylea II, Natpara, Omidria, Oracea, Orserdu I, Orserdu II, Rydapt, Spinraza, Vonjo I, Vonjo II, Xolair, Zejula, Zytiga, and others. The Ekterly is an oral on-demand therapy for treating attacks associated with Hereditary Angioedema (HAE). The Eylea I is a vascular endothelial growth factor inhibitor initially indicated for the treatment of neovascular wet age-related macular degeneration. Natpara is indicated as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism.

Directors

    Last Annual
    December 31st, 2025
    Last Interim
    March 31st, 2026
    Incorporated
    October 21st, 2020
    Public Since
    February 11th, 2021
    No. of Employees
    32
    Sector
    Pharmaceuticals
    Industry
    Healthcare
    Exchange
    ca flag iconToronto Stock Exchange
    Shares in Issue
    55,016,156

    DHT.UN Share Price Performance

    Upcoming Events for DHT.UN

    Q2 2026 Dri Healthcare Trust Earnings Release

    Q3 2026 Dri Healthcare Trust Earnings Release

    Similar to DHT.UN

    Picture of Aptose Biosciences logo

    Aptose Biosciences

    ca flag iconToronto Stock Exchange

    Picture of Aurora Cannabis logo

    Aurora Cannabis

    ca flag iconToronto Stock Exchange

    Picture of Auxly Cannabis logo

    Auxly Cannabis

    ca flag iconToronto Stock Exchange

    Picture of Bausch Health Companies logo

    Bausch Health Companies

    ca flag iconToronto Stock Exchange

    Picture of Canopy Growth logo

    Canopy Growth

    ca flag iconToronto Stock Exchange

    FAQ